Volume and value of pharma/biotech M&A slowed down in 2016

9 January 2017

Worldwide merger and acquisition activity in the pharmaceutical and biotechnology sector in 2016 was plentiful, but well down in numbers and values on that seen in the previous two years.

The number of transactions announced in 2016 was 130, according to The Pharma Letter tracking (see full table below) compared with 166 M&A deals in 2015 – which was a record year – and 137 in 2014. Moreover, the number of M&A transactions valued at in excess of $1 billion mark was also well down at just 23 in 2016, versus 30 in 2015 and 26 in 2014.

The total value of the top 10 completed deals in the first half of 2016 amounted to $67.2 billion versus $190.4 billion in first-half 2015, according to a KPMG report earlier this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK